The maximum hepatitis C treatment coverage will be achieved in Kazakhstan due to a 10-fold reduction of price for such innovative drugs as Sofosbuvir and Daclatasvir. This significant price reduction has become possible thanks to the agreement signed between SK-Pharmacy LLP and the United Nations Development Program.
According to Berik Sharip, the acting Chairman of the Board of SK-Pharmacy LLP, more than 1.5 billion tenge were allocated from the Kazakhstan’s state budget for procurement of Sofosbuvir and Daclatasvir.
“Since the United Nations Development Program, which organized the procurement of these drugs, managed to get a 10-fold reduction of the price, the entire allocated amount will be used to purchase these drugs. We will try to provide the latest treatment for viral hepatitis to as many patients registered in medical institutions with viral hepatitis C as possible,” said Berik Sharip.
Sofosbuvir is included in the WHO Essential Medicines List. In most cases, the treatment of viral hepatitis by Sofosbuvir and Daclatasvir allows to completely eliminate the virus from the body. In addition, such treatment has much less side effects than in case of previously used methods. Procurement of the drug has become possible thanks to the agreement signed between SK-Pharmacy LLP and the United Nations Development Program.